Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics Stock Analysis & Ratings

PLX Stock Chart & Stats

Day’s Range$1.06 - $1.11
52-Week Range$0.70 - $3.08
Previous Close$1.08
Average Volume (3M)2.75M
Market Cap$52.00M
P/E Ratio-1.7
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score4
EPS (TTM)-0.62



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $0.70 and its highest was $3.08 in the past 12 months.
    What is Protalix Biotherapeutics’s market cap?
    Protalix Biotherapeutics’s market cap is $52.00M.
      What is Protalix Biotherapeutics’s price target?
      Currently, no data Available
      What do analysts say about Protalix Biotherapeutics?
      Not enough analysts have published a price target to provide an average price target.
      When is Protalix Biotherapeutics’s upcoming earnings report date?
      Protalix Biotherapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 77 days.
        How were Protalix Biotherapeutics’s earnings last quarter?
        Currently, no data Available
        Is Protalix Biotherapeutics overvalued?
        According to Wall Street analysts Protalix Biotherapeutics’s price is currently Overvalued.
          Does Protalix Biotherapeutics pay dividends?
          Protalix Biotherapeutics does not currently pay dividends.
          What is Protalix Biotherapeutics’s EPS estimate?
          Protalix Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Protalix Biotherapeutics have?
          Protalix Biotherapeutics has 47,060,000 shares outstanding.
            What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Protalix Biotherapeutics?
            Among the largest hedge funds holding Protalix Biotherapeutics’s share is Highbridge Capital Management LLC. It holds Protalix Biotherapeutics’s shares valued at N/A.


              Protalix Biotherapeutics Stock Analysis

              Smart Score
              Price Target
              No data currently available
              The Protalix Biotherapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Protalix Biotherapeutics

              Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.

              Similar Stocks
              Price & Change
              Merck & Company

              Popular Stocks

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis